Intertek to Sponsor and Present at the Society of Toxicology of Canada Annual Symposium
13 Nov 2017
Intertek, a leading Total Quality Assurance provider to industries worldwide, is a proud sponsor of the annual Society of Toxicology of Canada (STC) symposium to be held November 29-December 1, 2017 in Montreal, Quebec.
The Society of Toxicology of Canada Inc. functions as a non-profit organization. Its company mission is to provide information on and solutions to scientific issues relating to toxicology. The STC supports continuing education and excellence in research through its annual symposium.
This 49th annual meeting will bring together members and international experts to present the latest developments in experimental and regulatory toxicology. This year's theme will focus on "Visualizing Toxicology in 4D: Disruption, Development and Drug Discovery". Attendees will benefit from global insights into “Drug Discovery to Development”, “Developmental Origins of Health and Disease”, “Impact of Chemicals on the Endocrine System”, and more.
Intertek Health, Environmental & Regulatory Services (HERS) is sponsoring the STC “Discovery to Development VIII” session as well as the student awards for recognizing scientific excellence of both MSc and PhD students of toxicology who attend the meeting. Intertek has supported two cash prizes awarded for the best poster presented by PhD or MSc students at the Symposium for 19 consecutive years. As the aim of the Society is to foster excellence in the science of toxicology, Intertek is very proud to work with the STC to be able to recognize scientific excellence among the next generation of toxicology professionals in this way. HERS expert, Mr. Lindsay Donald, VP, Pharmaceuticals, will be presenting these awards during the President’s reception held on the evening of November 30.
In addition to the awards ceremony, Mr. Lindsay Donald will also give a presentation on “Points to Consider in Developing Antibody-Drug-Conjugates (ADCs)” during Session I on November 30th at 9:00am. ADCs are a relatively new class of compounds and there are no regulatory guidelines which specifically address their development. There are several quite unique challenges which must be considered in their safety assessment including immunogenicity assay requirements and bioanalysis assay complexity. Mr. Donald states, “this class of compounds has challenges in toxicology preclinical testing that need to be fully addressed to avoid drug development delays in the clinic”. His presentation will discuss ADC preclinical study design, anti-drug antibody assay development and validation and other challenges to avoid failure due to safety issues.
To register for the event, please visit: http://www.stcweb.ca/en/events.shtml
To set-up a meeting during the show, please contact pharma.sci-reg@intertek.com
To learn more about the regulatory and scientific consultancy services offered by our experts and within the larger Intertek organization visit: intertek.com/pharmaceutical
About Intertek
Total Quality. Assured.
Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories and offices and over 42,000 people in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains. Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely.
Contact Information
Tracy Veale
Global Marketing Manager
T: +1 905 542 2900
E: tracy.veale@intertek.com
Lindsay Donald
VP, Pharmaceuticals, HERS
T: +1 905 542 2900
E: lindsay.donald@intertek.com